Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Biostatistics and Bioinformatics Shared Resource, University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Mol Cancer Res. 2021 Aug;19(8):1270-1282. doi: 10.1158/1541-7786.MCR-21-0025. Epub 2021 May 4.
Invasive lobular carcinoma (ILC) is the most common special histologic subtype of breast cancer, and nearly all ILC tumors express estrogen receptor alpha (ER). However, clinical and laboratory data suggest ILC are strongly estrogen-driven but not equally antiestrogen-sensitive. We hypothesized ILC-specific ER coregulators mediate ER functions and antiestrogen resistance in ILC, and profiled ER-associated proteins by mass spectrometry. Three ER ILC cell lines (MDA MB 134VI, SUM44PE, and BCK4) were compared with ER invasive ductal carcinoma (IDC) line data, and we examined whether siRNA of identified proteins suppressed ER-driven proliferation in ILC cells. This identified mediator of DNA damage checkpoint 1 (MDC1), a tumor suppressor in DNA damage response (DDR), as a novel ER coregulator in ILC. We confirmed ER:MDC1 interaction was specific to ILC versus IDC cells, and found MDC1 knockdown suppressed ILC cell proliferation and tamoxifen resistance. Using RNA-sequencing, we found in ILC cells MDC1 knockdown broadly dysregulates the ER transcriptome, with ER:MDC1 target genes enriched for promoter hormone response elements. Importantly, our data are inconsistent with MDC1 tumor suppressor functions in DDR, but suggest a novel oncogenic role for MDC1 as an ER coregulator. Supporting this, in breast tumor tissue microarrays, MDC1 protein was frequently low or absent in IDC, but MDC1 loss was rare in ER ILC. ER:MDC1 interaction and MDC1 coregulator functions may underlie ER function in ILC and serve as targets to overcome antiestrogen resistance in ILC. IMPLICATIONS: MDC1 has novel ER coregulator activity in ILC, which may underlie ILC-specific ER functions, estrogen response, and antiestrogen resistance.
浸润性小叶癌(ILC)是乳腺癌最常见的特殊组织学亚型,几乎所有的 ILC 肿瘤都表达雌激素受体α(ER)。然而,临床和实验室数据表明,ILC 强烈依赖雌激素,但对抗雌激素的敏感性并不相同。我们假设 ILC 特异性 ER 共激活剂介导 ILC 中的 ER 功能和抗雌激素耐药性,并通过质谱法对 ER 相关蛋白进行了分析。将三种 ER ILC 细胞系(MDA MB 134VI、SUM44PE 和 BCK4)与 ER 浸润性导管癌(IDC)细胞系的数据进行了比较,并研究了鉴定出的蛋白的 siRNA 是否能抑制 ILC 细胞中的 ER 驱动增殖。这鉴定出了 DNA 损伤检查点 1(MDC1)的调节剂,即 DNA 损伤反应(DDR)中的肿瘤抑制因子,作为 ILC 中的一种新的 ER 共激活剂。我们证实 ER:MDC1 相互作用是 ILC 与 IDC 细胞特异性的,并且发现 MDC1 敲低抑制了 ILC 细胞的增殖和他莫昔芬耐药性。通过 RNA-seq,我们发现 MDC1 敲低在 ILC 细胞中广泛失调 ER 转录组,其中 ER:MDC1 靶基因富含启动子激素反应元件。重要的是,我们的数据与 DDR 中 MDC1 肿瘤抑制因子的功能不一致,但提示 MDC1 作为 ER 共激活剂具有新的致癌作用。支持这一点,在乳腺癌组织微阵列中,MDC1 蛋白在 IDC 中经常低表达或缺失,但在 ER ILC 中很少缺失。ER:MDC1 相互作用和 MDC1 共激活剂功能可能是 ILC 中 ER 功能的基础,并可作为克服 ILC 中抗雌激素耐药性的靶点。意义:MDC1 在 ILC 中具有新型的 ER 共激活剂活性,这可能是 ILC 特异性 ER 功能、雌激素反应和抗雌激素耐药性的基础。